Introduction
Around 70% of International Space Station crew members develop Spaceflight‑Associated Neuro‑Ocular Syndrome (SANS), a condition that threatens vision on long‑duration missions.
Miniaturized photonic chip technology
Siloton, founded by physicists in 2020, has compressed the core optics of a conventional optometrist’s retinal thickness scanner onto a photonic chip smaller than a coin. The same hardware now supports octogenarians in the UK’s NHS to self‑scan at home, and ESA plans to adopt the exact specifications for upcoming Artemis lunar flights and future deep‑space voyages. Integrated lasers, interferometric sensors, and AI‑driven analysis enable rapid measurement of the retina’s posterior layers without a specialist on Earth.
Physiological causes and real‑world impact of SANS
In microgravity, bodily fluids shift toward the head, compressing the eyeball, swelling the optic nerve, and pushing the retina forward. NASA astronaut John Phillips exemplifies the risk: launched in 2005 with perfect 20/20 vision, he returned six months later with 20/100 acuity, a moderate impairment that could jeopardize mission tasks and persist after re‑entry.
Engineering obstacles unique to spaceflight
Traditional eye‑testing devices rely on lithium‑ion batteries, which pose a fire hazard in a sealed spacecraft. Siloton engineers are exploring solid‑state super‑capacitors and thermal‑energy harvesting to power the scanner safely. Additionally, the bulk of a binocular‑sized instrument must be accommodated within cramped modules, and a new head‑stabilization system—potentially using a magnetic or shape‑memory‑alloy cradle—must replace the gravity‑dependent chin rest used on Earth.
Dual‑benefit ripple effect for terrestrial healthcare
"The ESA pretty much has the same requirements," CTO Euan Allen explains, noting that the device is already being validated on 80‑year‑old patients with varying degrees of visual impairment. Success in space will feed back into the NHS, offering earlier detection of retinal diseases such as diabetic retinopathy. Moreover, autonomous scanning reduces reliance on real‑time ground support, a critical advantage when communication delays stretch to minutes on Mars‑bound missions.
Conclusion
SANS represents a major health risk for future explorers, but ESA’s collaboration with Siloton brings a compact, battery‑safe photonic scanner that can deliver continuous ocular monitoring. By providing early warnings and potentially averting permanent vision loss, the technology not only safeguards astronauts but also promises to elevate eye‑care standards on Earth.